Pbimmunetherapeutics
1 known investors
Seoul-based biotechnology company developing preclinical immune-focused therapeutics including Treg cell therapies and antibodies.
Also known as PB Immune Therapeutics · PB Immune Therapeutics, Inc
Investors · 1
Company profile
researched Aug 2026PB Immune Therapeutics, Inc is a biotechnology company based in Seoul, South Korea, with a corporate presence dated to 2020. Its work is classified in the biotechnology industry and focuses on immune-mediated conditions, with disease areas spanning immune system diseases, neoplasms, nervous system diseases, and endocrinology and metabolic disease.
The company's disclosed development activity is preclinical. Drug candidates associated with it include PB 201, in preclinical stage for autoimmune diseases; PB-202, in preclinical stage for graft-versus-host disease; and PB-203, a PDL1 x PGF-targeted PDL1 inhibitor originated by PB Immune Therapeutics and listed with Panolos Bioscience, Inc. among active organizations, in preclinical stage for indications including pancreatic cancer. Technology descriptors attached to the company include CAR-Treg, Treg cell therapy, Fc fusion proteins, monoclonal antibodies and exosomes, alongside targets such as PDL1 x PGF and CD40.
Traction
Three named pipeline candidates (PB 201, PB-202, PB-203) are recorded at preclinical stage, and no candidate has received a first approval in any territory.
▸Full profile — market position, technology, go-to-market, geography
Market position
The company is an early-stage biotechnology developer whose disclosed pipeline assets are all at preclinical phase, with no approvals recorded in any country.
Technology
Drug modalities associated with the company include CAR-Treg and regulatory T-cell (Treg) cell therapy, Fc fusion proteins, monoclonal antibodies, and exosomes. Named targets include a PDL1 x PGF bispecific approach (PDL1 inhibition) and CD40, a member of the tumor necrosis factor receptor superfamily.
Go-to-market
Development programs address patients with autoimmune diseases, graft-versus-host disease, and cancers including pancreatic cancer.
Geography
Headquartered in Seoul, South Korea.
Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
▸Research sources · 6
primary sources listed
- PB Immune Therapeutics, Incinsights.citeline.com · web
6 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Pbimmunetherapeutics do?
- Seoul-based biotechnology company developing preclinical immune-focused therapeutics including Treg cell therapies and antibodies.
- Who are Pbimmunetherapeutics's investors?
- Pbimmunetherapeutics's investors include Atinum Investment Co. Ltd..